Cell and gene therapy is evolving fast—and so are the tools that make it possible. At Revvity, we're helping scientists, developers, and manufacturers stay in rhythm with breakthrough innovations designed for precision, scalability, and regulatory confidence. Whether you're advancing gene editing technologies, optimizing therapeutic delivery, scaling up viral vectors, or ensuring quality control, our solutions are engineered to support you at every stage of your development journey.
- Explore how our portfolio supports in vivo, ex vivo, and cell therapy approaches
- Discover enabling technologies like Pin-point™ base editing, LentiBOOST™ transduction enhancer, LabChip™, and GMP-grade Cell-Vive™ reagents
- See how we help bridge the gap from discovery to delivery with tailored support across all five CGT development stages
- Meet our experts, experience the technology in motion, and discover how Revvity can help you hit the right notes in your next therapeutic breakthrough.
Join Revvity at ASGCT 2025 – Booth #1111
Discover how we support your therapy from discovery to delivery.
What's new
Cell-Vive™ GMP MojoSort™ Streptavidin Nanobeads
This column-free, magnetic bead-based system uses high-affinity biotin-conjugated antibodies for positive or negative selection of targeted cells. Our GMP Streptavidin Nanobeads boast low endotoxin levels and are manufactured under animal component-free conditions. .
HostDetect™ HEK293 PCR DNA Quant Kit
This real-time PCR assay (RUO) enables quantitative detection of residual HEK293 host genomic DNA in extracted nucleic acid samples from biopharmaceutical products.
LabChip Plasmid DNA (pDNA) Assay
The LabChip™ Plasmid DNA assay is designed to streamline your plasmid (pDNA) workflows. It separates the three primary isoforms of pDNA in under 2 minutes/sample while providing purity assessment based on the corrected area percentages for each conformation.
Revvity's ASGCT 2025 Welcome Yellow Party
Kick off ASGCT with an unforgettable night of dancing, singing, eating, and drinking alongside your industry peers! Join us at the Hard Rock Café on Bourbon Street for great food, drinks, and live music from our own house band, Molecular Groovve.
Let’s come together to jazz up the future of cell & gene therapy – with science, innovation, and community in perfect harmony!
Featured technologies
Pin-point™ Base Editing Platform
Transformative technology enabling single nucleotide changes without double-strand DNA breaks, for precision and reduced off-target effects.
Highly effective transduction enhancer for research and clinical application of lentiviral vectors in a wide range of cell types.
BioLegend’s Cell-Vive™ Portfolio
Serum-free, GMP-certified reagents designed for ex vivo cell processing and downstream manufacturing.
Cell Counting & Image Cytometry Instruments
Automated systems for accurate cell health, viability, and immunophenotyping assessments.
Cell and Gene Therapy Research Reagents
A range of discovery and bioanalytical immunoassays for the development and research of CGT therapies.
Experience and innovation in AAV engineering and development to help accelerate your gene therapy’s journey to the clinic.
Viral Vector Engineering and Manufacturing
Comprehensive suite of viral vector services.
Our CGT ecosystem – Built for your journey
Identifying and validating disease-relevant genetic targets while facilitating efficient screening, cell characterization, and early gene editing—without compromising data quality or speed.
Delivering therapeutic payloads efficiently into target cells—while minimizing toxicity, immune response, and variability across viral and non-viral systems.
Bridging the gap between discovery and clinical trials requires robust tools to assess viability, expression, toxicity, and mechanism of action—across increasingly complex 3D models and in vivo systems.
Moving from small-scale experiments to clinical-grade production requires optimized processes, GMP-aligned reagents, and consistent vector performance—all while maintaining speed and regulatory readiness.
Helping every batch to meet regulatory expectations for identity, purity, potency, and stability—while streamlining testing workflows and reducing delays.
Our CGT ecosystem – Tailored for your therapy type
In vivo gene therapy delivers genetic material directly into the patient’s cells—typically using viral vectors such as AAV or lipid nanoparticles. These therapies are often designed for long-term or permanent correction with a single administration.
Ex vivo gene therapy involves harvesting a patient’s cells, genetically modifying them in vitro, and then re-infusing them. It facilitates tighter control over editing and characterization, often used in hematologic or immune-based therapies.
Cell therapy leverages the body’s natural cellular abilities to address complex health challenges, without altering the genetic makeup of the cells.
Meet us at ASGCT
Let’s Jam - Meet Our Experts at Booth #1111
Oral Presentation
Enhancing AAV Production Efficiency: A Dual Approach to Design of Experiments Optimization and Economic Feasibility Analysis
Session: Upstream Manufacturing for AAV Vectors
Date: May 17, 2025
Time: 10:15 AM - 12:00 PM
Room: NOLA Theater C
Abstract Presentation Time: 11:15 AM - 11:30 AM
Small-Scale Manufacturing of Innovative rAAV Capsid Variants for Enhanced Retinal Gene Therapy
Session: AAV Vector Manufacturing: Process Development
Date: May 13, 2025
Time: 1:30 PM - 3:15 PM
Room: NOLA Theater B
Abstract Presentation Time: 2:45 PM - 3:00 PM
Posters
A single-step process for non-viral engineering of hypoimmunogenic pluripotent stem cells with the Pin-point™ base editing platform
Thursday Poster Reception
May 15, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I3
Customizing the versatile Pin-point™ platform: Modular components for tailored base editing in genomic applications
Thursday Poster Reception
May 15, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I3
Design and Assembly of Modular Pin-point™ Base Editors for Precise Correction of Pathogenic SNVs
Wednesday Poster Reception
May 14, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I2
Gene Delivery Vector Comparison Study Using the Celigo™ Image Cytometer
Thursday Poster Reception
May 15, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I3
One-step engineering of allogeneic CAR-T cells by simultaneous multiplex knockout and site-specific transgene integration with the Pin-point™ base editing platform configured with OpenCRISPR-1, an AI-engineered CRISPR-Cas enzyme
Thursday Poster Reception
May 15, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I3
A base editing platform optimised for efficient editing retains stemness and differentiation potential of hematopoietic stem cells
Wednesday Poster Reception
May 14, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I3
Minimal activation of the p53 DNA damage response by a modular cytosine base editor enables effective multiplexed gene knockout in induced pluripotent stem cells.
Thursday Poster Reception
May 15, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I2
Precise and Efficient Immune Cell Engineering via Pin-point™ Base Editing Platform: Insights from TotalSeq Single-Cell Multiomic Analysis
Thursday Poster Reception
May 15, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I2
Beyond the Dot Blot: A Novel Method for dsRNA Detection for Gene Therapies
Tuesday Poster Reception
May 13, 2025
6:00 PM - 7:30 PM
Poster Hall I2
Development of a SMARTvector™ Multiplex shRNA Platform for Complex Cell Therapy Engineering with a Single Vector
Tuesday Poster Reception
May 13, 2025
6:00 PM - 7:30 PM
Poster Hall I2
Optimization of the modular Pin-point™ base editing platform for an engineered Type V CRISPR-Cas effector
Thursday Poster Reception
May 15, 2025
5:30 PM - 7:00 PM
Poster Hall Hall I2